Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study
This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase. Two-year continuation rates of prescription at discharge were examined using a retrospective cohort study method. Adult patients with schiz...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 2017-06, Vol.37 (3), p.296-301 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 301 |
|---|---|
| container_issue | 3 |
| container_start_page | 296 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 37 |
| creator | Yoshimura, Yusaku Takeda, Toshihiko Kishi, Yoshiki Harada, Toshiki Nomura, Akira Washida, Kenji Yoshimura, Bunta Sato, Kojiro Yada, Yuji Aoki, Shozo |
| description | This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase.
Two-year continuation rates of prescription at discharge were examined using a retrospective cohort study method. Adult patients with schizophrenia and related psychotic disorders, receiving antipsychotic monotherapy with RIS or OLZ at discharge, were included. The primary outcome measures were the time to treatment discontinuation and 2-year continuation rates at 4 modal dose ranges of each drug. We estimated the optimal tolerability dose ranges by comparing the continuation rates at various modal doses.
Of 648 patients, 344 received RIS and 304 received OLZ. The RIS 2-year continuation rates at 4 daily modal dose ranges were significantly different (0.5-2.5 mg: 46.0%, 3.0-5.0 mg: 40.0%, 5.5-7.5 mg: 30.0%, and 8.0-10.0 mg: 28.0%), with the difference favoring RIS at lower doses (0.5-5.0 mg) more than higher doses (5.5-10.0 mg). In contrast, there were no significant differences among OLZ 4 modal dose ranges (2.5-7.5 mg: 49.1%, 10.0-15.0 mg: 42.6%, 17.5-22.5 mg: 40.9%, and 25.0-30.0 mg: 39.0%). The time to treatment discontinuation significantly favored OLZ over RIS. However, it did not significantly differ between RIS and OLZ at lower doses.
It is suggested that the optimal tolerability dose range during maintenance treatment is 0.5 to 5.0 mg/d for RIS and 2.5 to 30 mg/d for OLZ, and that RIS at lower doses is comparable with OLZ at lower doses. |
| doi_str_mv | 10.1097/JCP.0000000000000689 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1878825387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1878825387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-4696377a2fb6301ceb41084a1ce5e33663b0fba2f71e95f73fdd9f1b963c46fd3</originalsourceid><addsrcrecordid>eNpdUc1O3DAQtlARLJQ3qCofewm148ROuKGlpUWgXQEVvUWOPW6MsnZqO5WWZ-IhcYFWVecyY833Y82H0DtKjilpxceL5fqY_Fu8aXfQgtaMFYKW39-gBSkFLYio2n10EOM9IbQSZb2H9suGEc4pX6DH1ZTsRo74zEfrfmBv8LWNEwSrvQMsncarUboHOdn8tA6nAfCVtC6Bk04Bvg0g0wZcwsYHvJbJ5jniO5sGfKMG--CnIYCz8lnrGkaZQON13KrBJ6vwmY0-aAjxBJ_mdQo-u6tkf2WbecyILAcB36RZb9-iXSPHCEev_RB9-_zpdvmluFydf12eXhaqrHkqKt5yJoQsTc8ZoQr6ipKmknmqgTHOWU9Mn9eCQlsbwYzWraF9ZqmKG80O0YcX3Sn4nzPE1G1sVDDmQ4CfY0cb0TRlzRqRodULVOWPxwCmm0K-Z9h2lHS_c-pyTt3_OWXa-1eHud-A_kv6Ewx7Alb8kc0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1878825387</pqid></control><display><type>article</type><title>Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study</title><source>Journals@Ovid Complete - AutoHoldings</source><source>MEDLINE</source><creator>Yoshimura, Yusaku ; Takeda, Toshihiko ; Kishi, Yoshiki ; Harada, Toshiki ; Nomura, Akira ; Washida, Kenji ; Yoshimura, Bunta ; Sato, Kojiro ; Yada, Yuji ; Aoki, Shozo</creator><creatorcontrib>Yoshimura, Yusaku ; Takeda, Toshihiko ; Kishi, Yoshiki ; Harada, Toshiki ; Nomura, Akira ; Washida, Kenji ; Yoshimura, Bunta ; Sato, Kojiro ; Yada, Yuji ; Aoki, Shozo</creatorcontrib><description>This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase.
Two-year continuation rates of prescription at discharge were examined using a retrospective cohort study method. Adult patients with schizophrenia and related psychotic disorders, receiving antipsychotic monotherapy with RIS or OLZ at discharge, were included. The primary outcome measures were the time to treatment discontinuation and 2-year continuation rates at 4 modal dose ranges of each drug. We estimated the optimal tolerability dose ranges by comparing the continuation rates at various modal doses.
Of 648 patients, 344 received RIS and 304 received OLZ. The RIS 2-year continuation rates at 4 daily modal dose ranges were significantly different (0.5-2.5 mg: 46.0%, 3.0-5.0 mg: 40.0%, 5.5-7.5 mg: 30.0%, and 8.0-10.0 mg: 28.0%), with the difference favoring RIS at lower doses (0.5-5.0 mg) more than higher doses (5.5-10.0 mg). In contrast, there were no significant differences among OLZ 4 modal dose ranges (2.5-7.5 mg: 49.1%, 10.0-15.0 mg: 42.6%, 17.5-22.5 mg: 40.9%, and 25.0-30.0 mg: 39.0%). The time to treatment discontinuation significantly favored OLZ over RIS. However, it did not significantly differ between RIS and OLZ at lower doses.
It is suggested that the optimal tolerability dose range during maintenance treatment is 0.5 to 5.0 mg/d for RIS and 2.5 to 30 mg/d for OLZ, and that RIS at lower doses is comparable with OLZ at lower doses.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/JCP.0000000000000689</identifier><identifier>PMID: 28306616</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - pharmacology ; Benzodiazepines - administration & dosage ; Benzodiazepines - pharmacology ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment (Health Care) ; Psychotic Disorders - drug therapy ; Retrospective Studies ; Risperidone - administration & dosage ; Risperidone - pharmacology ; Schizophrenia - drug therapy ; Young Adult</subject><ispartof>Journal of clinical psychopharmacology, 2017-06, Vol.37 (3), p.296-301</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-4696377a2fb6301ceb41084a1ce5e33663b0fba2f71e95f73fdd9f1b963c46fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28306616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshimura, Yusaku</creatorcontrib><creatorcontrib>Takeda, Toshihiko</creatorcontrib><creatorcontrib>Kishi, Yoshiki</creatorcontrib><creatorcontrib>Harada, Toshiki</creatorcontrib><creatorcontrib>Nomura, Akira</creatorcontrib><creatorcontrib>Washida, Kenji</creatorcontrib><creatorcontrib>Yoshimura, Bunta</creatorcontrib><creatorcontrib>Sato, Kojiro</creatorcontrib><creatorcontrib>Yada, Yuji</creatorcontrib><creatorcontrib>Aoki, Shozo</creatorcontrib><title>Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase.
Two-year continuation rates of prescription at discharge were examined using a retrospective cohort study method. Adult patients with schizophrenia and related psychotic disorders, receiving antipsychotic monotherapy with RIS or OLZ at discharge, were included. The primary outcome measures were the time to treatment discontinuation and 2-year continuation rates at 4 modal dose ranges of each drug. We estimated the optimal tolerability dose ranges by comparing the continuation rates at various modal doses.
Of 648 patients, 344 received RIS and 304 received OLZ. The RIS 2-year continuation rates at 4 daily modal dose ranges were significantly different (0.5-2.5 mg: 46.0%, 3.0-5.0 mg: 40.0%, 5.5-7.5 mg: 30.0%, and 8.0-10.0 mg: 28.0%), with the difference favoring RIS at lower doses (0.5-5.0 mg) more than higher doses (5.5-10.0 mg). In contrast, there were no significant differences among OLZ 4 modal dose ranges (2.5-7.5 mg: 49.1%, 10.0-15.0 mg: 42.6%, 17.5-22.5 mg: 40.9%, and 25.0-30.0 mg: 39.0%). The time to treatment discontinuation significantly favored OLZ over RIS. However, it did not significantly differ between RIS and OLZ at lower doses.
It is suggested that the optimal tolerability dose range during maintenance treatment is 0.5 to 5.0 mg/d for RIS and 2.5 to 30 mg/d for OLZ, and that RIS at lower doses is comparable with OLZ at lower doses.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Benzodiazepines - administration & dosage</subject><subject>Benzodiazepines - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Outcome Assessment (Health Care)</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Retrospective Studies</subject><subject>Risperidone - administration & dosage</subject><subject>Risperidone - pharmacology</subject><subject>Schizophrenia - drug therapy</subject><subject>Young Adult</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdUc1O3DAQtlARLJQ3qCofewm148ROuKGlpUWgXQEVvUWOPW6MsnZqO5WWZ-IhcYFWVecyY833Y82H0DtKjilpxceL5fqY_Fu8aXfQgtaMFYKW39-gBSkFLYio2n10EOM9IbQSZb2H9suGEc4pX6DH1ZTsRo74zEfrfmBv8LWNEwSrvQMsncarUboHOdn8tA6nAfCVtC6Bk04Bvg0g0wZcwsYHvJbJ5jniO5sGfKMG--CnIYCz8lnrGkaZQON13KrBJ6vwmY0-aAjxBJ_mdQo-u6tkf2WbecyILAcB36RZb9-iXSPHCEev_RB9-_zpdvmluFydf12eXhaqrHkqKt5yJoQsTc8ZoQr6ipKmknmqgTHOWU9Mn9eCQlsbwYzWraF9ZqmKG80O0YcX3Sn4nzPE1G1sVDDmQ4CfY0cb0TRlzRqRodULVOWPxwCmm0K-Z9h2lHS_c-pyTt3_OWXa-1eHud-A_kv6Ewx7Alb8kc0</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Yoshimura, Yusaku</creator><creator>Takeda, Toshihiko</creator><creator>Kishi, Yoshiki</creator><creator>Harada, Toshiki</creator><creator>Nomura, Akira</creator><creator>Washida, Kenji</creator><creator>Yoshimura, Bunta</creator><creator>Sato, Kojiro</creator><creator>Yada, Yuji</creator><creator>Aoki, Shozo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study</title><author>Yoshimura, Yusaku ; Takeda, Toshihiko ; Kishi, Yoshiki ; Harada, Toshiki ; Nomura, Akira ; Washida, Kenji ; Yoshimura, Bunta ; Sato, Kojiro ; Yada, Yuji ; Aoki, Shozo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-4696377a2fb6301ceb41084a1ce5e33663b0fba2f71e95f73fdd9f1b963c46fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Benzodiazepines - administration & dosage</topic><topic>Benzodiazepines - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Outcome Assessment (Health Care)</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Retrospective Studies</topic><topic>Risperidone - administration & dosage</topic><topic>Risperidone - pharmacology</topic><topic>Schizophrenia - drug therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshimura, Yusaku</creatorcontrib><creatorcontrib>Takeda, Toshihiko</creatorcontrib><creatorcontrib>Kishi, Yoshiki</creatorcontrib><creatorcontrib>Harada, Toshiki</creatorcontrib><creatorcontrib>Nomura, Akira</creatorcontrib><creatorcontrib>Washida, Kenji</creatorcontrib><creatorcontrib>Yoshimura, Bunta</creatorcontrib><creatorcontrib>Sato, Kojiro</creatorcontrib><creatorcontrib>Yada, Yuji</creatorcontrib><creatorcontrib>Aoki, Shozo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshimura, Yusaku</au><au>Takeda, Toshihiko</au><au>Kishi, Yoshiki</au><au>Harada, Toshiki</au><au>Nomura, Akira</au><au>Washida, Kenji</au><au>Yoshimura, Bunta</au><au>Sato, Kojiro</au><au>Yada, Yuji</au><au>Aoki, Shozo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>37</volume><issue>3</issue><spage>296</spage><epage>301</epage><pages>296-301</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><abstract>This study aims to determine the optimal tolerability dose ranges of risperidone (RIS) and olanzapine (OLZ) administered during schizophrenia maintenance phase.
Two-year continuation rates of prescription at discharge were examined using a retrospective cohort study method. Adult patients with schizophrenia and related psychotic disorders, receiving antipsychotic monotherapy with RIS or OLZ at discharge, were included. The primary outcome measures were the time to treatment discontinuation and 2-year continuation rates at 4 modal dose ranges of each drug. We estimated the optimal tolerability dose ranges by comparing the continuation rates at various modal doses.
Of 648 patients, 344 received RIS and 304 received OLZ. The RIS 2-year continuation rates at 4 daily modal dose ranges were significantly different (0.5-2.5 mg: 46.0%, 3.0-5.0 mg: 40.0%, 5.5-7.5 mg: 30.0%, and 8.0-10.0 mg: 28.0%), with the difference favoring RIS at lower doses (0.5-5.0 mg) more than higher doses (5.5-10.0 mg). In contrast, there were no significant differences among OLZ 4 modal dose ranges (2.5-7.5 mg: 49.1%, 10.0-15.0 mg: 42.6%, 17.5-22.5 mg: 40.9%, and 25.0-30.0 mg: 39.0%). The time to treatment discontinuation significantly favored OLZ over RIS. However, it did not significantly differ between RIS and OLZ at lower doses.
It is suggested that the optimal tolerability dose range during maintenance treatment is 0.5 to 5.0 mg/d for RIS and 2.5 to 30 mg/d for OLZ, and that RIS at lower doses is comparable with OLZ at lower doses.</abstract><cop>United States</cop><pmid>28306616</pmid><doi>10.1097/JCP.0000000000000689</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 2017-06, Vol.37 (3), p.296-301 |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1878825387 |
| source | Journals@Ovid Complete - AutoHoldings; MEDLINE |
| subjects | Adolescent Adult Antipsychotic Agents - administration & dosage Antipsychotic Agents - pharmacology Benzodiazepines - administration & dosage Benzodiazepines - pharmacology Female Humans Male Middle Aged Outcome Assessment (Health Care) Psychotic Disorders - drug therapy Retrospective Studies Risperidone - administration & dosage Risperidone - pharmacology Schizophrenia - drug therapy Young Adult |
| title | Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T06%3A21%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20Dosing%20of%20Risperidone%20and%20Olanzapine%20in%20the%20Maintenance%20Treatment%20for%20Patients%20With%20Schizophrenia%20and%20Related%20Psychotic%20Disorders:%20A%20Retrospective%20Multicenter%20Study&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=Yoshimura,%20Yusaku&rft.date=2017-06-01&rft.volume=37&rft.issue=3&rft.spage=296&rft.epage=301&rft.pages=296-301&rft.issn=0271-0749&rft.eissn=1533-712X&rft_id=info:doi/10.1097/JCP.0000000000000689&rft_dat=%3Cproquest_cross%3E1878825387%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1878825387&rft_id=info:pmid/28306616&rfr_iscdi=true |